PURPOSE: Long-term human papillomavirus (HPV) infection is a prerequisite for cervical cancer. IL-1beta and IL-1Ra expression levels play an important role in cervical carcinogenesis. Several functional genetic variants in IL1B and IL-RN have been reported to be associated with IL-1beta expression and cancer susceptibility. In the current study, we hypothesized that plasma IL-1beta levels, IL-1B and IL-RN polymorphisms were candidate biomarkers for cervical cancer. METHODS: We measured plasma IL-1beta levels and genotyped IL-1B and IL-RN polymorphisms in a case-control study of 404 cervical cancer cases and 404 controls in Chinese women. RESULTS: The mean plasma IL-1beta levels in cervical cancer cases (42.19 +/- 31.55 pg/ml) was significantly higher than those in controls (34.86 +/- 22.68 pg/ml, P = 0.0002), and plasma IL-1beta levels above the 75% quartiles in controls (IL-1beta > or = 46.94 pg/ml) were associated with a 1.74-fold significantly increased risk of cervical cancer [95% confidence interval (CI), 1.28-2.36], compared with those of lowest quartile. Multivariate logistic regression analyses revealed that the variant genotypes, IL-1B T-31C TC/CC and C-511T CT/TT, were associated with a significantly increased risk of cervical cancer [adjusted odds ratio (OR), 1.60; 95% CI, 1.16-2.21 for -31TC/CC, and adjusted OR, 1.52; 95% CI, 1.10-2.09 for -511CT/TT, respectively), especially among subjects having higher levels of IL-1beta. However, IL-RN VNTR polymorphism was not associated with cervical cancer risk in the current study. Furthermore, the significant differences of IL-1beta concentration between cervical cancer cases and controls were observed only among subjects carrying T-31C or C-511T variant genotypes. CONCLUSION: Functional IL-1B genotypes may modify plasma IL-1beta concentrations to contribute to the etiology of cervical cancer in Chinese women; however, further perspective studies are warranted to test the causal effects of IL-1beta concentration in cervical carcinogenesis.
PURPOSE: Long-term human papillomavirus (HPV) infection is a prerequisite for cervical cancer. IL-1beta and IL-1Ra expression levels play an important role in cervical carcinogenesis. Several functional genetic variants in IL1B and IL-RN have been reported to be associated with IL-1beta expression and cancer susceptibility. In the current study, we hypothesized that plasma IL-1beta levels, IL-1B and IL-RN polymorphisms were candidate biomarkers for cervical cancer. METHODS: We measured plasma IL-1beta levels and genotyped IL-1B and IL-RN polymorphisms in a case-control study of 404 cervical cancer cases and 404 controls in Chinese women. RESULTS: The mean plasma IL-1beta levels in cervical cancer cases (42.19 +/- 31.55 pg/ml) was significantly higher than those in controls (34.86 +/- 22.68 pg/ml, P = 0.0002), and plasma IL-1beta levels above the 75% quartiles in controls (IL-1beta > or = 46.94 pg/ml) were associated with a 1.74-fold significantly increased risk of cervical cancer [95% confidence interval (CI), 1.28-2.36], compared with those of lowest quartile. Multivariate logistic regression analyses revealed that the variant genotypes, IL-1BT-31C TC/CC and C-511T CT/TT, were associated with a significantly increased risk of cervical cancer [adjusted odds ratio (OR), 1.60; 95% CI, 1.16-2.21 for -31TC/CC, and adjusted OR, 1.52; 95% CI, 1.10-2.09 for -511CT/TT, respectively), especially among subjects having higher levels of IL-1beta. However, IL-RN VNTR polymorphism was not associated with cervical cancer risk in the current study. Furthermore, the significant differences of IL-1beta concentration between cervical cancer cases and controls were observed only among subjects carrying T-31C or C-511T variant genotypes. CONCLUSION: Functional IL-1B genotypes may modify plasma IL-1beta concentrations to contribute to the etiology of cervical cancer in Chinese women; however, further perspective studies are warranted to test the causal effects of IL-1beta concentration in cervical carcinogenesis.
Authors: J Bidwell; L Keen; G Gallagher; R Kimberly; T Huizinga; M F McDermott; J Oksenberg; J McNicholl; F Pociot; C Hardt; S D'Alfonso Journal: Genes Immun Date: 1999-09 Impact factor: 2.676
Authors: José Carlos Machado; Céu Figueiredo; Paulo Canedo; Paul Pharoah; Ralph Carvalho; Sérgio Nabais; Catarina Castro Alves; Maria Luisa Campos; Leen-Jan Van Doorn; Carlos Caldas; Raquel Seruca; Fátima Carneiro; Manuel Sobrinho-Simões Journal: Gastroenterology Date: 2003-08 Impact factor: 22.682
Authors: Christoph Grimm; Ingrid Berger; Caroline Tomovski; Robert Zeillinger; Nicole Concin; Sepp Leodolter; Heinz Koelbl; Clemens B Tempfer; Lukas A Hefler Journal: Gynecol Oncol Date: 2004-03 Impact factor: 5.482
Authors: Hugo Sousa; Alexandra M Santos; Raquel Catarino; Daniela Pinto; José Moutinho; Paulo Canedo; José Carlos Machado; Rui Medeiros Journal: Mol Biol Rep Date: 2012-10-10 Impact factor: 2.316
Authors: Ajay V Maker; Nora Katabi; Li-Xuan Qin; David S Klimstra; Mark Schattner; Murray F Brennan; William R Jarnagin; Peter J Allen Journal: Clin Cancer Res Date: 2011-01-25 Impact factor: 12.531
Authors: Ajay V Maker; Vincent Hu; Shrihari S Kadkol; Lenny Hong; William Brugge; Jordan Winter; Charles J Yeo; Thilo Hackert; Markus Büchler; Rita T Lawlor; Roberto Salvia; Aldo Scarpa; Claudio Bassi; Stefan Green Journal: J Am Coll Surg Date: 2019-02-19 Impact factor: 6.113